N

Novavax
D

NVAX

8.66000
USD
0.09
(1.05%)
Market Open
Volume
8,488
EPS
1
Div Yield
-
P/E
-4
Market Cap
1,387,202,048
OverviewSignalsIdeasNews
Related Instruments
    A
    AEMD
    -0.03940
    (-4.98%)
    0.75100 USD
    A
    ALT
    0.15500
    (2.18%)
    7.27000 USD
    AZN
    AZN
    0.395
    (0.60%)
    66.290 USD
    BNTX
    BNTX
    0.160
    (0.14%)
    115.500 USD
    C
    CEMI
    0.02200
    (6.47%)
    0.35000 USD
    C
    CODX
    -0.03670
    (-4.89%)
    0.71330 USD
    I
    INO
    0.02500
    (1.38%)
    1.83500 USD
    JNJ
    JNJ
    -0.100
    (-0.07%)
    143.980 USD
    MRK
    MRK
    -0.250
    (-0.25%)
    99.060 USD
    MRNA
    MRNA
    -0.480
    (-1.14%)
    41.540 USD
    PFE
    PFE
    -0.040
    (-0.15%)
    26.575 USD
    V
    VXRT
    0.06910
    (9.61%)
    0.78810 USD
    More
News

Title: Novavax

Sector: Healthcare
Industry: Biotechnology
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.